PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Orphenadrine hydrochloride - Parkinson's disease
PAD Profile : Orphenadrine hydrochloride - Parkinson's disease
Keywords :
anticholinergics, motor fluctuations, dyskinesia, PD
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Tolcapone
- Apomorphine hydrochloride
- Safinamide
- Opicapone
- Co-beneldopa (Benserazide/levodopa)
- Co-careldopa (Carbidopa/levodopa)
- Pramipexole
- Ropinirole hydrochloride
- Bromocriptine
- Pergolide mesilate
- Cabergoline
- Rasagiline mesilate
- Selegiline hydrochloride
- Entacapone
- Amantadine hydrochloride
- Procyclidine hydrochloride
- Trihexyphenidyl hydrochloride
- Clonazepam
- Melatonin
- Rotigotine
- Levodopa/carbidopa/entacapone
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
NICE does not recommend the use of anticholinergics in Parkinson's disease for patients who have developed dyskinesia and / or motor fluctuations.
Associated BNF Codes
04. Central Nervous System
04.09.02. Antimuscarinic drugs used in parkinsonism